Viatris hosted its first Investor Day (view slides), and the company provided updates across its diabetes generics and biosimilars portfolio. Importantly, the company disclosed plans to develop a generic version of Novo Nordisk’s Rybelsus (oral semaglutide). Below, FENIX provides brief highlights from the Investor Day as well as insight into challenges and questions of generic Rybelsus development.